Minerva Neurosciences (NERV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 3, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 2, 2026.
Voting matters and shareholder proposals
Election of two Class III directors to serve until the 2029 annual meeting, with board recommending both nominees.
Proposal to amend the charter to allow officer exculpation under Delaware law.
Proposal to amend the charter to eliminate the exclusive forum provision.
Advisory vote on executive compensation and on the preferred frequency of future say-on-pay votes.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends all proposals, including director nominees and charter amendments.
Proxies are authorized to vote on other business that may arise at the meeting.
Latest events from Minerva Neurosciences
- Six key proposals, including governance and compensation changes, are up for vote at the 2026 meeting.NERV
Proxy filing23 Apr 2026 - Six key proposals, including director elections and charter amendments, headline the 2026 annual meeting.NERV
Proxy filing10 Apr 2026 - Registering up to $200M in securities to fund CNS drug development and corporate growth.NERV
Registration Filing11 Mar 2026 - 2025 net loss driven by non-cash charges; Phase 3 trial for roluperidone set for Q2 2026.NERV
Q4 202511 Mar 2026 - Roluperidone targets negative symptoms in schizophrenia, with a pivotal phase III trial underway.NERV
The Citizens Life Sciences Conference 202610 Mar 2026 - Roluperidone advances as a leading candidate for negative symptoms, with robust data and funding.NERV
KOL event3 Feb 2026 - Q3 2025 net loss of $2.7M; $80M raised for Phase 3 roluperidone trial, up to $120M more possible.NERV
Q3 202512 Jan 2026 - Q1 2025 net loss narrowed to $3.8M; regulatory and funding risks remain significant.NERV
Q1 202512 Jan 2026 - Q3 net income surged on a $26.6M royalty gain, but regulatory and Nasdaq risks persist.NERV
Q3 202412 Jan 2026